Caspofungin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Caspofungin: From Antifungal Therapy to Gastrin Secretion Abnormality
One-Sentence Summary
Caspofungin is an echinocandin-class antifungal agent; its confirmed original indication and detailed mechanism of action are currently not available in this evidence pack (data gap pending TFDA/DrugBank confirmation). The TxGNN model predicts a possible association with Gastrin Secretion Abnormality, but this prediction is currently supported by 0 clinical trials and 0 publications, and no biological mechanism linking the two has been established.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no confirmed indication data in this evidence pack (see Data Gap DG002) |
| Predicted New Indication | Gastrin Secretion Abnormality |
| TxGNN Prediction Score | 99.44% (model rank 5983) |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for caspofungin is not confirmed in this evidence pack (Data Gap DG002, High severity). Based on general pharmacological class knowledge referenced in the model's own rationale, caspofungin is an echinocandin-class antifungal that inhibits fungal 1,3-β-D-glucan synthase — a cell-wall-synthesis target that does not exist in human cells.
The repurposing rationale accompanying this prediction explicitly states that no known pharmacological or mechanistic pathway connects glucan synthase inhibition to gastrin secretion regulation (e.g., G-cell function, gastrin receptors, H⁺/K⁺-ATPase, or somatostatin signaling). Because both the original indication and MOA fields are marked as data gaps, no biological plausibility can currently be established for this candidate.
This prediction should be treated as a raw TxGNN model output without mechanistic support. It requires independent pharmacological review before any further evaluation is warranted.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Caspofungin is not currently marketed in Taiwan (0 authorizations on record); no product license or approved-indication data is available.
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA package insert warnings/contraindications are currently unavailable (Data Gap DG001, Blocking severity) — this gap prevents the candidate from proceeding to the S1 safety pre-assessment stage. Drug interaction (DDI) data was also queried with no results found.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has only model-level (L5) evidence with no clinical trials or literature support, and no mechanistic link between caspofungin's known antifungal MOA and gastrin secretion abnormality has been established. In addition, a Blocking-severity data gap (missing TFDA package insert) prevents entry into safety pre-assessment.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) to unblock S1 safety review
- Confirmed original indication and detailed MOA data (DrugBank/TFDA)
- Preclinical or mechanistic studies establishing biological plausibility for the gastrin-related pathway
- Any emerging clinical trial or literature evidence for this drug-disease pair
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.